Patents for A61P 35 - Antineoplastic agents (221,099)
01/2006
01/18/2006EP1616563A2 Perivascular administration of anti-angiogenic factors for treating or preventing vascular diseases
01/18/2006EP1615952A2 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
01/18/2006EP1615932A2 Podophhyllotoxin derivatives as igf-1r inhibitors
01/18/2006EP1615928A1 Pyrimido compounds
01/18/2006EP1615921A2 Pyrido 2,3-d pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
01/18/2006EP1615906A1 Compositions useful as inhibitors of protein kinases
01/18/2006EP1615898A1 2-aminopyrimidine derivatives and their medical use
01/18/2006EP1615671A1 Microspheres comprising therapeutic and diagnostic radioactive isotopes
01/18/2006EP1615668A1 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy
01/18/2006EP1615667A2 Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
01/18/2006EP1615665A2 Delivery of immune response modifier compounds
01/18/2006EP1615659A2 Use of bv8 and/or eg-vegf to promote hematopoiesis
01/18/2006EP1615658A1 Inhibition of tumor cell proliferation by foxm1b inhibitors
01/18/2006EP1615650A1 Phosphate derivatives of pharmaceutical products
01/18/2006EP1615640A2 Antineoplastic combinations
01/18/2006EP1615639A2 Targeted bone marrow protection agents
01/18/2006EP1615638A1 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy
01/18/2006EP1615611A2 iRNA CONJUGATES
01/18/2006EP1615552A2 Sapphyrins and uses thereof
01/18/2006EP1512016B1 Screening method and anti-tumor drug candidate obtained therefrom
01/18/2006EP1470138B1 Mmp inhibitors
01/18/2006EP1435951B1 Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
01/18/2006EP1412338B1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists
01/18/2006EP1404672B1 Tyrosine kinase inhibitors
01/18/2006EP1286663B1 Encapsulating a toxic core within a non-toxic region in an oral dosage form
01/18/2006EP1278851B1 Humanised antibodies to the epidermal growth factor receptor
01/18/2006EP1268096B1 Extrusion die
01/18/2006EP1255733B1 Farnesyl transferase inhibitors
01/18/2006EP1232183B1 Peptides having antiangiogenic activity
01/18/2006EP1220852B1 Substituted diazepans
01/18/2006EP1212335B1 Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- 4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
01/18/2006EP1210327B1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments
01/18/2006EP1127068B1 Immunotherapeutic methods using epitopes of wt-1 and gata-1
01/18/2006EP0973727B8 Activated iododerivatives for the treatment of cancer and aids
01/18/2006CN1723207A Inhibitors of histone deacetylase
01/18/2006CN1723201A Blood-brain barrier disruption inhibitors
01/18/2006CN1723196A Fluoropyrrolidines as dipeptidyl peptidase inhibitors
01/18/2006CN1723193A Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof
01/18/2006CN1723192A Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
01/18/2006CN1723038A Pharmaceutical composition for inducing an immune response in a human or animal
01/18/2006CN1723037A Methods and compositions for promoting the maturation of monocytes
01/18/2006CN1723029A Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
01/18/2006CN1721553A Methods for assessing and treating cancer
01/18/2006CN1721533A Fusion protein of IL2 and single chain antibody against GD2, its encoding genes and use thereof
01/18/2006CN1721447A Modified peptides as therapeutic agents
01/18/2006CN1721445A Degraded TPO agonist antibody
01/18/2006CN1721444A Nucleotide and protein sequences of Nogo genes and methods based thereon
01/18/2006CN1721442A Proteins producing an altered immunogenic response and methods of making and using the same
01/18/2006CN1721438A Human secreted protein hCGI-143
01/18/2006CN1721436A Modified tumor antigen peptide and use thereof
01/18/2006CN1721428A Compound and method for treating cancer
01/18/2006CN1721426A Anthraquinone glycoside compounds containing glucopyranoside group and use thereof
01/18/2006CN1721416A Substituted methylene pyrones derivatives and their preparing process and use
01/18/2006CN1721412A 7-oxo pyridopyrimidines
01/18/2006CN1721401A Inhibitors of LFA-1 binding to ICAMS and uses thereof
01/18/2006CN1721397A Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
01/18/2006CN1720999A Hab18G/CD147 molecule small segment interfering RNA medicine and application thereof
01/18/2006CN1720998A Preparation and application of pig interleukin-2 gene anti-infectious preparation
01/18/2006CN1720997A Method for preparing antineoplastic nanometer heat sensitive target medicine carrier
01/18/2006CN1720996A Antineoplastic nanometer heat sensitive target medicine carrier used combined with chemical therapy and heat therapy
01/18/2006CN1720995A The treatment of respiratory diseases
01/18/2006CN1720994A Treatment of refractory human tumors with epidermal growth factor receptor antagonists
01/18/2006CN1720992A Treatment for central nervous system lymphoma
01/18/2006CN1720991A Degraded agonist antibody
01/18/2006CN1720990A Degraded agonist antibody
01/18/2006CN1720984A Medicine for treating hysteromyoma and its preparation method
01/18/2006CN1720921A Antineoplastic medicinal composition, its preparation method and application
01/18/2006CN1720910A Application of Cytospora bacterin B in preparation of antineoplastic medicine
01/18/2006CN1720901A Temperature controllable heat therapeutic embolizing sponge powder an its preparation process
01/18/2006CN1237178C Use and constructing plan of anticancer recombined gland virus with tumour CHK1 as target of medicine
01/18/2006CN1237177C Use and obtain of selective inactivating tumour PLK1 anticancer recombined gland virus constituent
01/18/2006CN1237176C Method for remodelling cell wall polysaccharide structures in plants
01/18/2006CN1237170C Method of proliferating natural killer cells
01/18/2006CN1237076C Polypeptide variants with altered effector function
01/18/2006CN1237075C Low molecular weight peptide derivatives as inhibitors of laminin/nidogen interaction
01/18/2006CN1237070C Biomolecule with therapeutic tumour action and its use
01/18/2006CN1237065C Composition of norcantharidin with anticancer drugs containing platinum and its usage
01/18/2006CN1237062C Ortho-substituted anthranilic acid amides and their use as medicaments
01/18/2006CN1237061C Chemokine receptor binding heterocyclic compounds
01/18/2006CN1236815C Application of integrin antagonists in preparation of medicine for treating multiple myeloma and myeloma-induced bone resorption
01/18/2006CN1236790C Anticancer Chinese herbal medicine powder and its preparation process
01/18/2006CN1236782C Java brucea oil-emulsion injecta with low-toxicity and preparing method thereof
01/18/2006CN1236771C Liposome of 10-hydroxycamptothecine, and its prepn. method
01/18/2006CN1236767C Vitronectin receptor antagonists
01/18/2006CN1236760C Liposomes containing entrapped compound in supersaturated solution
01/18/2006CA2572427A1 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
01/17/2006US6987193 Illudin analogs useful as antitumor agents
01/17/2006US6987184 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
01/17/2006US6987168 Tryptase inhibitor proteins derived from blood-feeding anthropod ectoparasites
01/17/2006US6987123 A substituted pyrrole-1-yl-alkyloxy-aryl-2-alkyloxypropanoate derivatives, antilipiemic agents, anticholesterol agents
01/17/2006US6987122 Antitumor agents; solid tumors of rectum, lungs
01/17/2006US6987119 Pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them and anticancer agents
01/17/2006US6987116 Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
01/17/2006US6987113 3-hetero-arylideneazaindolin-2-one compounds
01/17/2006US6987110 Such as 3-(1-(2-hydroxyethyl)-1H-indol-3-yl)-4-(1-(3-pyridinyl)-1H-indol-3-yl)-1H -pyrrole-2,5-dione
01/17/2006US6987109 Solubilized topoisomerase poison agents
01/17/2006US6987108 Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
01/17/2006US6987103 Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents
01/17/2006US6987102 Methods to mobilize progenitor/stem cells
01/17/2006US6987100 Pharmaceutical compositions for treating bone lesions in multiple myeloma